While controlling health care costs is an important goal, price controls are a short-sighted tool that threaten the engine of biopharmaceutical innovation. roi-nj.com/2025/05/29/opi…

NEW Op-Ed: #PBMs jack up prices, dominate the market, and dodge accountability. As Congress targets fraud and abuse in health spending, PBMs and their spread pricing should be priority number one. Learn more here: dcjournal.com/to-lower-presc…

Must read in the dcjournal: “Instead of imposing destructive price control policies, policymakers should instead focus on reining in the Pharmacy Benefit Manager industry.” dcjournal.com/to-lower-presc…

“New Jersey Alzheimer’s patients and their caregivers deserve better options, and that will only happen if we continue to support robust biopharmaceutical research and reject short-sighted policies that threaten its future.” tapinto.net/towns/phillips…

New from Patients First Org in RealClearHealth: “This new pilot program marks a critical step toward restoring integrity and refocusing the program on its original purpose of putting patients first.” #340BReform realclearhealth.com/articles/2025/…

The U.S. GAO has warned for years that #340B has grown far beyond its intent - driving higher drug costs, fueling abuse, and lacking oversight. Today’s Senate hearing is a chance to simplify the system and restore its purpose. bio.org/putting-americ…

The 340B program should be about patients, not profits. Today’s Senate HELP hearing underscores the need for reforms to make sure drug discounts actually get to the patients who need them. 💊🩺

In a new op-ed, PatientsComeFirstNJ Executive Director warns that junk science is enabling trial lawyers to override medical expertise in health care decisions, putting patients at risk. Read more: patientscomefirst.com/news/northjers…